About Liquidia
Liquidia is a company based in United States founded in 2004. Liquidia has raised $75.3 million across 12 funding rounds from investors including Gates Foundation, NIST and Canaan. The company has 157 employees. Liquidia has completed 1 acquisition, including Raregen. Liquidia operates in a competitive market with competitors including Sirnaomics, Acorda, Genedit, NanoSyrinx and Ensysce, among others.
- Headquarter United States
- Employees 157
- Stage Public
- SectorsTechnologyHealthcare
- Website liquidia.com
- Social LinkedIn
- Legal Name Liquidia Corporation
- Annual Revenue$158.32 M (USD)1031.18as on Dec 31, 2025
- Net Profit-$68.92 M (USD)46.28as on Dec 31, 2025
- EBITDA-$49.85 M (USD)58.15as on Dec 31, 2025
- Total Equity Funding$75.3M (USD)
in 12 rounds
- Latest Funding Round$21.7M (USD), Post-IPO
Apr 2021
- InvestorsGates Foundation
& 12 more
- Employee Count157
- Investments & Acquisitions
Funding Insights of Liquidia
Liquidia has successfully raised a total of $75.3M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.7 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $75.3M
- Total Rounds 12
- Last Round Post-IPO — $21.7M
- First Round $6M
(Jun 2006)
- Investors Count 13
Latest 10 of 12 funding rounds of Liquidia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $21.7M | Post-IPO | – | – | – |
| Jan 2020 | $22.42M | Post-IPO | – | – | – |
| Feb 2018 | $25.5M | Series D | – | – | |
| May 2013 | $1.89M | Grant | – | – | |
| Jul 2012 | $13.8M | Series C | – | – | – |
| Mar 2011 | $10M | Grant | – | – | |
| Jul 2010 | $5M | Series C | – | – | |
| Jan 2010 | $25M | Series C | – | Canaan, Pappas Capital | |
| Dec 2009 | $3M | Grant | – | – | |
| Dec 2009 | $2.97M | Grant | – | – |
13 investors in total: 13 institutional.
Investors in Liquidia
Liquidia has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Gates Foundation, NIST and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are directed toward early and late-stage companies. | – | amereus.com | Singapore, Singapore | |
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Multiple sectors are invested in by Morningside, a VC fund. | – | morningside.com | Newton, United States | |
VC firm focusing on life science sector | – | pappas-capital.com | Durham, United States | |
- | – | firelakecapital.com | - | |
- | – | wakefieldgroup.com | - | |
Venture investments in systems, infrastructure, and applications for enterprise founders. | – | next47.com | - | |
Financial services are provided to healthcare companies by Revelation Partners. | 2013 | revelation-partners.com | San Francisco, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Liquidia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Liquidia
53 people are tracked at Liquidia (26 in leadership, 7 in board & advisors, 20 in team); the tracked headcount is 157.
| Name | Role | Group |
|---|---|---|
Damian Degoa | Director | Leadership |
Dana B. | Chief Accounting Officer | Leadership |
Sean Y. | Senior Director, Commercial Ops & Analytics | Leadership |
Mike Kaseta | CFO | Leadership |
Rajeev Saggar | Chief Medical Officer | Leadership |
Sarah Krepp | Chief Human Resources Officer | Leadership |
Roger Jeffs | CEO | Leadership |
Michael Hunter | Sr. Vice President, Manufacturing Operations | Leadership |
Mark Bailey | Regional Business Director - Northeast (rare Disease) | Leadership |
Frank L Bartolini | Senior Vice President Of Market Access | Leadership |
Matt Snow | Senior Vice President Of Sales | Leadership |
Marisa del Hierro | Sr. Director, Regulatory And PV Operations | Leadership |
Jason Adair | Chief Business Officer | Leadership |
Laura M. | Senior Director, Key Account Development | Leadership |
Jackie Morrison-Haddad | Regional Business Director, West Area | Leadership |
Derek Schorzman | Vice President, Manufacturing Sciences | Leadership |
Brandon Knez | Director Of Accounting | Leadership |
Gareth Gwyn | Vice President Medical Affairs | Leadership |
Jeff Kindig | Vice President, Quality | Leadership |
Michelle Gallant | Senior Director, U.s. Marketing | Leadership |
33 more people are available in the full profile.
Complete people profiles for Liquidia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Liquidia
Liquidia is a publicly listed company on the NASDAQ with ticker symbol LQDA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Jul 2018
- Listed onNASDAQ: LQDA
- Listed entityLiquidia Corporation
- Exchange sectorHealth technology
- ISINUS53635D2027
- Share price$28.02 (+5.02% on the day) · 2026-10-08
- Market capitalisation$2.51B
- Price to earnings20.5
- EPS (diluted, trailing year)$1.36
- Volume (last session)5,259,541
Financials of Liquidia
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $158.3M | -$68.9M | -$49.9M |
| 2024 | $14.0M | -$128.3M | -$119.1M |
| 2023 | $17.5M | -$78.5M | -$71.2M |
| 2022 | $15.9M | -$41.0M | -$34.8M |
| 2021 | $15.5M | -$34.6M | -$27.9M |
Detailed financial statements for Liquidia
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Liquidia
Liquidia has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Raregen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Strategy planning and investment consulting are provided for healthcare sectors. | raregenllc.com | Durham, United States | 2018 | Jun 2020 | •••• |
Complete acquisition details for Liquidia
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Liquidia
5 dated milestones of Liquidia across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Liquidia is founded.
- Funding First funding round of $6.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Raregen.
- Funding Latest funding round, Post-IPO, of $21.7M.
Competitors of Liquidia
Liquidia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Acorda, Genedit, NanoSyrinx and Ensysce, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sirnaomics.com | 2007 | Gaithersburg, United States | $267M | 88 | RNA-based therapeutics for cancer and fibrosis are developed. | |
| acorda.com | 1995 | Ardsley, United States | $66.5M | 109 | Engaged in the development and commercialization of therapies that improve neurological function. | |
| genedit.com | 2016 | Berkeley, United States | $93.5M | 34 | Genetic medicines are delivered using polymer nanoparticle platforms. | |
| nanosyrinx.com | 2018 | Coventry, United Kingdom | $21.63M | 17 | Drug delivery systems to cell interiors are developed via nanosyringes. | |
| ensysce.com | 2008 | Houston, United States | $2.5M | – | Drug delivery solutions via single-walled carbon nanotubes are offered. | |
| arcturusrx.com | 2013 | San Diego, United States | $1.3M | 337 | RNAi technologies are developed for treating rare orphan diseases. | |
| clene.com | 2012 | Salt Lake, United States | $59.1M | 99 | Nanotechnology-based therapeutics for cancer and auto-immune disorders are developed. | |
| erydel.com | 2007 | Milan, Italy | $31.7M | – | Erythrocyte encapsulation systems for drug delivery are developed. | |
| viaqua-t.com | 2014 | Rehovot, Israel | $12.55M | – | RNAi drug delivery technology is developed for aquaculture disease prevention. |
Detailed competitors of Liquidia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Liquidia
The website of Liquidia (liquidia.com) receives about 17.2K visits a month.
- Monthly visits17.2K
▲ 39.6% vs previous month
Websites whose visitors overlap most with Liquidia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| atdbio.com | 100% | 29.3K | #886,988 | View details | |
| eurochem.co.uk | 100% | – | – | View details | |
capsulution.com | capsulution.com | 100% | – | #3,311,802 | – |
| hybridplastics.com | 100% | 1.8K | #6,871,765 | View details | |
bionanomatrix.com | bionanomatrix.com | 100% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Liquidia
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Liquidia
Complete news archive for Liquidia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Liquidia
10 companies that operate in the same segment as Liquidia (Nanotechnology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | – | USD 648.1 M | – | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 | |
Nanotech-based electrode materials for supercapacitors are provided. | 2009 | Boston, Massachusetts, United States | USD 163.32 M | – | 66 | |
Instrument systems and software for single-molecule real-time sequencing are developed. | 2004 | Menlo Park, California, United States | USD 395 M | USD 160 M | 575 | |
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Conductive nanocoatings are delivered via atomic layer deposition technology. | 2013 | Boulder, Colorado, United States | USD 202.75 M | – | – | |
RNA therapeutics for hematology and cardiovascular diseases are developed. | 1999 | London, England, United Kingdom | – | USD 559 K | 116 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Liquidia
Liquidia was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Liquidia is headquartered in United States.
Liquidia is a funded company, having raised a total of $75.3M across 12 funding rounds to date. The company's 1st funding round was a Grant of $2.97M, raised on Jun 2006.
Liquidia has 157 employees.
Annual revenue of Liquidia is $158.32M as on Dec 31, 2025.
Liquidia Technologies was founded in 2004 in the United States. Engineered particles and films are developed and manufactured for applications in life sciences and materials sciences. Micro- and nanoparticles are created for delivering biological and small molecule therapeutics, as well as for vaccines and inhaled treatments. Nano-patterned optical films are produced for displays, lighting, photovoltaics, and related uses.
Liquidia's top competitors include Sirnaomics, Arcturus Therapeutics and Acorda.
Yes, Liquidia is publicly traded on NASDAQ under the ticker symbol LQDA.
Liquidia has made 1 acquisition, including Raregen.
Liquidia has 13 investors. Key investors include Gates Foundation, NIST, Canaan, Revelation Partners, and Amereus.